Precision Psychiatry Market To Reach $2,858.0 Million By 2033

September 2025 | Report Format: Electronic (PDF)

Precision Psychiatry Market Growth & Trends

The global precision psychiatry market is projected to reach USD 2.86 million by 2033, growing at a CAGR of 14.91% from 2025 to 2033, according to a new report by Grand View Research, Inc. The global precision psychiatry industry is experiencing substantial expansion due to an increasing desire for personalized methods to the treatment of mental health issues, improved treatment results, and growing awareness of the limitations of traditional “trial-and-error” psychiatry. The escalation of investment in genomics, digital health, and biomarker discovery has heightened the urgency for personalized diagnostic and therapeutic solutions and contributed to the uptake of genetic testing, pharmacogenomic assays, and AI-enabled clinical decision support platforms. Also, in addition to a recent increased regulatory emphasis on improving mental health care, supportive government and institutional actions are driving momentum in this market today.

Innovation in precise psychiatry is powered by a strong ecosystem of research institutes, mental health professionals, and biopharmaceutical companies. Pharmaceutical companies, laboratories that provide diagnostic tests, and digital health companies are now unifying to integrate genomics, neuroimaging, and evidence from the real world into psychiatric care pathways.

With the technological advancements of the next-generation sequencing (NGS), neuroimaging, and machine learning algorithms, precision psychiatry enables more precise diagnosis, drug-response prediction, and management of complex psychiatric conditions. The role of precision psychiatry will be essential for all conditions, including depression, anxiety, schizophrenia, and bipolar disorder, to improve therapeutic efficiency and reduce adverse drug responses.

The development of strategic partnerships, the growing use of pharmacogenomic testing, and the ongoing innovation of AI-enabled platforms reinforce its role as a crucial driver for delivering personalized, effective, and evidence-based mental health care within the transforming life sciences and healthcare ecosystem.

key Request a free sample copy or view report summary: Precision Psychiatry Market Report

Precision Psychiatry Market Report Highlights

By service type, the genetic testing segment accounted for the largest share of 41.21% in 2024, due to the increasing utilization of pharmacogenomic testing, biomarkers, and polygenic risk scoring in psychiatric care. Genetic testing is increasingly part of a clinician's toolbox for making evidence-based decisions around treatment selection, predicting response to treatment, and minimizing adverse events. Growing accessibility to genomic testing platforms and increasing patient awareness of precision treatment options further substantiate the size of this service type.
By technology, the next-generation sequencing (NGS) segment dominated the market with a share of 46.52% in 2024, owing to its ability to deliver high-throughput, precise, and cost-efficient genomic insights for psychiatric disorders. NGS allows for the discovery of novel variants, rare mutations, and polygenic risk factors specifically for complex disorders such as depression, schizophrenia, or bipolar disorder.
By therapeutic area, the depression and anxiety disorders segment held the largest share of 33.89% in 2024, driven by the high global prevalence of these disorders and the urgent need for more efficient and individualized treatment options. Precision psychiatry tactics, such as pharmacogenomic testing, neuroimaging, and digital biomarkers, are widely employed to mitigate treatment resistance and optimize care. The increasing burden of mental health disorders and more awareness of precision approaches help maintain this segment's dominant position.
By end-user, the hospitals & clinics segment captured the largest market share of 55.72% in 2024, because these healthcare entities serve as the primary focal points for integrating precision psychiatry into everyday patient care. Hospitals and clinics will continue to advance their use of genetic testing, digital therapeutics, and AI-enabled clinical decision support tools to provide patient treatments that are most suited for that patient. They have unique access to advanced diagnostic technologies, professionals with training and experience, and the ability to assemble multidisciplinary teams to deliver care that places them as the largest end user of this market.